tubulin inhibitor 7

Tubulin inhibitor 7 is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines (tubulin polymerization (IC50: 0.52 μM), K562 cell growth (IC50: 11 nM)).

Tubulin inhibitor 24 is a potent inhibitor that can inhibit tubulin polymerization.

URAT1 inhibitor 7 is a novel and potent inhibitor of the human uric acid transporter protein URAT1 (IC50:12 nM).URAT1 inhibitor 7 inhibits CYP2C9 with an IC50 of 4.2 μM.URAT1 inhibitor 7 can be used to study hyperuricemia and gout.

T.cruzi Inhibitor is a Trypanosoma cruzi inhibitor.

Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.

Tubulin inhibitor 8 is an inhibitor of tubulin and various cancer cell lines and inhibits tubulin polymerisation and K562 cell growth with an IC50 of 0.73 μM and 14 nM respectively.

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

C-Myc Inhibitor 7, serving as both a c-Myc inhibitor and a multi-target protein degrader, effectively degrades proteins c-MYC, CK1α, GSPT1, and IKZF1/2/3 across various tumor cell types. It holds potential for research into diseases associated with high c-Myc expression, including cancer, cardiovascular and cerebrovascular conditions, and viral infections.

PI3Kα Inhibitor 7 is a useful organic compound for research related to life sciences. The catalog number is T9312 and the CAS number is 1239978-63-2.

KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

Protein kinase inhibitor H-7 (5-(2-methylpiperazine-1-sulfonyl)isoquinoline) is a potent inhibitor of protein kinase C (PKC) with a Ki of 6 μM. Protein kinase inhibitor H-7 is also a cyclic nucleotide dependent protein kinase inhibitor.

Tubulin Inhibitor 28 (compound 2g), with an IC50 value of 1.2 μM, is a potent inhibitor of tubulin that exhibits significant anti-proliferative activity against MCF-7 cells [1].

Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor that inhibits tubulin assembly and bounds in the colchicine site (IC 50 = 1.2 μM). Tubulin inhibitor 29 exhibits antiproliferative effects with an IC 50 value of 7.5 μM for MCF-7 cells. [1].

Tubulin aggregation-IN-7 is a potent tubulin aggregation inhibitor that has shown research potential for cancer diseases.

Tubulin Inhibitor 37 (Compound 12) effectively impedes tubulin aggregation (IC50 = 1.3 µM) and demonstrates antiproliferative activity against human tumor cell lines, showing promise for cancer research [1].

Tubulin Inhibitor 38 (Compound 14), a tetrazole-based agent, demonstrates significant antiproliferative effects by inducing mitotic arrest and blocking the cell cycle at the G2/M phase, ultimately triggering apoptosis. Administered at 100 nM for 24 hours, it shows considerable cytotoxicity and selectivity within HeLa, MCF7, and U87 MG cell lines [1].

Tubulin Inhibitor 36 (Compound 10) serves as a potent novel inhibitor of tubulin polymerization, which consequently induces apoptosis in glioblastoma cells, reflected by an IC50 value of 1.5±0.1 μM. Exhibiting significant anti-mitotic activity, this compound demonstrates anti-tumor potential, particularly useful in glioblastoma multiforme (GBM) research [1].

Tubulin Inhibitor 33 is a dose-dependent inhibitor of tubulin polymerization, exhibiting an IC50 value of 9.05 μM. This compound demonstrates antitumor activity and induces apoptosis, making it useful for antitumor research [1].

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. Tubulin inhibitor 14 is a microtubule destabilizer with potential tumor-selective as well as anti-angiogenic and vascular-destructive properties [1].

Tubulin inhibitor 1 is an inhibitor of tubulin, inhibits tubulin polymerization, with potent anti-tumor activity, induces cellular apoptosis causes and cellular mitotic arrest in the G2/M phase.

PI3K/mTOR Inhibitor-7 is a potent dual PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-7 is 4.7-fold more potent than gedatolisib, with IC50 values of 1.4 μM and 0.3 μM, respectively. 10 μM of PI3K/mTOR Inhibitor-7 is able to significantly inhibit the PI3K/Akt/mTOR signalling pathway. PI3K/mTOR Inhibitor-7 has shown potential for research in cancer diseases.

Topoisomerase I inhibitor 7 (Compound 8) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 7 significantly inhibits tumor growth (up to 79%) and increases the lifespan (153%) of mice bearing P388 lymphoma transplants.

Protein kinase inhibitor H-7 dihydrochloride(H-7 dihydrochloride) is a potent protein kinase C (PKC) inhibitor. Protein kinase inhibitor H-7 dihydrochloride (100 μM) significantly inhibits TPA (skin tumor promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) inhibited PMA-induced promiscuity cell lysis activity.

Chitin synthase inhibitor 7 (compound 9c) is a potent inhibitor of chitin synthase (CHS) (IC50: 0.37 nM). synthase inhibitor 7 can be used to study fungal infections.

FGFR1 Inhibitor 7 (compound 5), a potent FGFR1 tyrosine kinase inhibitor, exhibits an IC50 of 0.33 nM against its target and demonstrates broad-spectrum cytotoxicity against human cancer cell lines. Additionally, it inhibits MOLT3 cells with an IC50 of 2.1 μM [1].

Tuberculosis inhibitor 7 (compound 2d), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, exhibits potent activity against Mycobacterium tuberculosis and Mycobacterium marinum, with both displaying a MIC 90 of 0.63 μM [1].

Tubulin Inhibitor 21 (compound 6f), a hybrid based on chalcone and melatonin, exhibits potent tubulin inhibition properties. It demonstrates significant cytotoxic activity against SW480 cells (IC 50 =0.26 μM) while showing lesser effects on nonmalignant cells [1].

ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).

GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM). GSK-3β inhibitor 7 acts by inserting into the ATP-binding binding pocket of GSK-3β and forming hydrogen bonds. GSK-3β inhibitor 7 has a high rate of glucose uptake by hepatocytes ( 83.5%) and can be used to study a variety of diseases such as cancer, diabetes, inflammation, Alzheimer's disease and bipolar disorder.

Tubulin inhibitor 12 (Hit 9) is a recently developed compound with potent inhibitory effects on tubulin (IC50 = 25.3 μM). This compound exhibits noteworthy anti-tumor and anti-proliferative activities, making it a promising candidate for the treatment of cancer [1].

α- Synuclein inhibitor 7 (compound 3gf) is effective α- Synuclein ( α- Syn) aggregation inhibitor, IC50 is 1.95 μM, inhibition rate at 30μM was 85.8%. α- Synuclein inhibitor 7 has blood-brain barrier permeability.

Glyoxalase I inhibitor 7 (Compound 6) is a potent inhibitor of glyoxalase I (Glo-I) with an IC50 of 3.65 μM. It exhibits potential as an anticancer agent [1].

Tubulin inhibitor 26 (compound 3c) is an indazole derivative which is a potent tubulin inhibitor with noteworthy low nanomolar potency against HepG2, HCT116, SW620, HT29 and A549 cancer cell lines. Tubulin inhibitor 26 inhibits tumor cell in G2/M phase as well as induces cell apoptosis. Tubulin inhibitor 26 suppresses the growth of tumor in vivo without affecting the mice body weight [1].

RIP1 Kinase Inhibitor 7 (Compound 41) serves as a potent inhibitory agent for receptor interacting protein 1 kinase (RIP1) with an IC50 of under 100 nM. Additionally, it demonstrates an EC50 ranging from 1 to 100 nM in cell necrosis assays [1].

SIRT5 inhibitor 7 (compound 58), a selective and substrate-competitive SIRT5 inhibitor, exhibits anti-inflammatory properties by modulating protein succinylation and attenuating pro-inflammatory cytokine release. It demonstrates renal protective effects and is active in vivo, showing efficacy in AKI mouse models subjected to lipopolysaccharide (LPS) and cecal ligation/perforation (CLP)-induced sepsis-related acute kidney injury [1].

Tie2 Inhibitor 7 blocks Tie2 kinase activity with a Ki value of 1.3 μM.. It has been shown to inhibit angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling with an IC50 value of 0.3 μM. This compound can prevent endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization.

HIV-1 integrase inhibitor 7 is a potent HIV-1 integrase inhibitor (IC50: 33.3 nM).

Tubulin inhibitor 23 is a potent Tubulin inhibitor (IC50: 4.8 μM). Tubulin inhibitor 23 exhibited antiangiogenic effects in a dose-dependent manner and could induce apoptosis. Tubulin inhibitor 23 has potential for leukemia research.

Tubulin inhibitor 20 (compound 1) shows the potential for the cancer research that is a potent tubulin inhibitor [1].

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound that exhibits strong inhibitory activity against tubulin. Its potential in cancer research makes it valuable for studying cancer diseases [1].

Tubulin Inhibitor 27 (DYT-1), a compound that inhibits tubulin polymerization with an IC50 of 25.6 μM, exhibits anti-angiogenesis and antitumor activities [1].

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM). Tubulin inhibitor 17 exhibits anticancer activities as well as induces cell apoptosis[1].

ATX inhibitor 7 is a autotaxin inhibitor and shows good oral exposure.

Tubulin Inhibitor 34 (compound b5), a potent anticancer agent, inhibits tubulin polymerization and induces G2/M arrest and apoptosis. The compound demonstrates significant antivascular and antitumor activity [1].

PI3Kγ Inhibitor 7 (compound 2) is a potent, orally active agent that selectively inhibits PI3Kγ with an IC50 of 3.42 nM and demonstrates antitumor activity [1]. It also exhibits varying inhibitory effects on other PI3K isoforms, with IC50 values of 4768 nM for PI3Kα, 878.1 nM for PI3Kβ, and 355.2 nM for PI3Kδ.

Tubulin inhibitor 16 is a potent tubulin inhibitor with antiproliferative activity. Tubulin inhibitor 16 exhibits cytotoxicity in HepG2 cells [1].

Compounds 17o (IC50= 14.0 nM, NCI-H460) and 17p (IC50= 2.9 nM, NCI-H460) with furan moieties show potent nanomolar levels of cytotoxic activity against various human cancer cell lines.

Topoisomerase II inhibitor 7, a potent inhibitor of the topoisomerase II alpha subtype, exhibits an IC50 of 3.19 μM. It effectively induces cell cycle arrest and apoptosis.